BSE Live
Oct 10, 16:01Prev. Close
9236.60
Open Price
9203.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 10, 15:55Prev. Close
9242.50
Open Price
9270.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of AstraZeneca Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 1,713.29 | 1,295.53 | 1,002.97 | 805.60 | 813.56 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 1,713.29 | 1,295.53 | 1,002.97 | 805.60 | 813.56 | |
Total Operating Revenues | 1,716.29 | 1,295.53 | 1,002.97 | 805.60 | 813.56 | |
Other Income | 40.63 | 34.80 | 26.10 | 14.76 | 12.84 | |
Total Revenue | 1,756.92 | 1,330.33 | 1,029.07 | 820.36 | 826.40 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 287.13 | 129.02 | 84.38 | 89.61 | 97.26 | |
Purchase Of Stock-In Trade | 1,008.82 | 499.31 | 324.46 | 207.88 | 194.74 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -332.94 | -33.77 | -48.86 | 14.47 | 2.95 | |
Employee Benefit Expenses | 257.44 | 241.45 | 259.10 | 230.21 | 219.54 | |
Finance Costs | 1.46 | 1.20 | 0.63 | 0.95 | 1.09 | |
Depreciation And Amortisation Expenses | 39.99 | 14.94 | 16.26 | 16.95 | 20.13 | |
Other Expenses | 241.87 | 275.07 | 218.77 | 177.25 | 163.60 | |
Total Expenses | 1,503.77 | 1,127.22 | 854.74 | 737.32 | 699.31 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 253.15 | 203.11 | 174.33 | 83.04 | 127.09 | |
Exceptional Items | -96.79 | 16.43 | -40.23 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 156.36 | 219.54 | 134.10 | 83.04 | 127.09 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 60.10 | 53.55 | 38.30 | 22.63 | 34.83 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -19.92 | -0.90 | -3.49 | -1.19 | -1.04 | |
Tax For Earlier Years | 0.44 | 5.38 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 40.62 | 58.03 | 34.81 | 21.44 | 33.79 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 115.74 | 161.51 | 99.29 | 61.60 | 93.30 | |
Profit/Loss From Continuing Operations | 115.74 | 161.51 | 99.29 | 61.60 | 93.30 | |
Profit/Loss For The Period | 115.74 | 161.51 | 99.29 | 61.60 | 93.30 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | |
Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 60.00 | 40.00 | 20.00 | 5.00 | 5.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 1,600.00 | 1,200.00 | 800.00 | 500.00 | 100.00 |
31.07.2025
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
07.04.2025
10.03.2025
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
17.02.2025
AstraZeneca Standalone December 2024 Net Sales at Rs 440.29 crore, up 43.98% Y-o-Y
21.11.2024
AstraZeneca Standalone September 2024 Net Sales at Rs 408.00 crore, up 31.16% Y-o-Y
13.08.2024
AstraZeneca Standalone June 2024 Net Sales at Rs 387.52 crore, up 31.16% Y-o-Y